Infections in Patients with hematological-oncological Diseases

被引:0
|
作者
Schmidt-Hieber, M. [1 ]
Christopeit, M. [2 ]
Schalk, E. [3 ]
机构
[1] HELIOS Klin, Klin Hamatol Onkol & Tumorimmunol, Schwanebecker Chaussee 50, D-13125 Berlin, Germany
[2] Univ Klinikum Hamburg Eppendorf, Klin Stammzelltransplantat, Hamburg, Germany
[3] Otto von Guericke Univ, Klin Hamatol & Onkol, Magdeburg, Germany
来源
NOTFALL & RETTUNGSMEDIZIN | 2017年 / 20卷 / 03期
关键词
WORKING-PARTY AGIHO; CLINICAL-PRACTICE GUIDELINE; NEUTROPENIC CANCER-PATIENTS; BLOOD-STREAM INFECTIONS; FEBRILE NEUTROPENIA; GERMAN-SOCIETY; ANTIMICROBIAL THERAPY; AMERICAN SOCIETY; MANAGEMENT; COMPLICATIONS;
D O I
10.1007/s10049-016-0257-3
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Infections represent a frequent and severe complication of patients with hematological-oncological disorders. The individual infection risk is determined by the presence of various risk factors such as the type of antineoplastic treatment. The purpose of this work was to determine the incidence of infections in patients with hematological-oncological disorders. The spectrum of causative agents and risk factors in these patients are also described and recommendations on diagnostic workup and antimicrobial treatment are given. Selective literature search, discussion of expert opinions. Infections in cancer patients may involve different organ systems and might be caused by bacteria, fungi, viruses, and parasites. Common infection types include febrile neutropenia in addition to other bacterial and viral infections (e. g., herpes zoster). Patients with high-risk neutropenia (absolute neutrophile count < 100/A mu l for > 7 days) and recipients of an allogeneic hematopoietic stem cell transplantation also show an increased risk for fungal (e. g., pulmonary aspergillosis) and parasitic infections (e. g., CNS toxoplasmosis). Diagnosis is based on routine procedures (such as blood cultures) and clinically-driven investigations (e. g., CT scan of the lungs). Antimicrobial treatment might be empiric, preemptive, or targeted. Infections significantly contribute to morbidity and mortality of patients with hematological-oncological disorders. The timely initiation of adequate diagnostics and antimicrobial treatment is crucial to reduce the mortality in these patients.
引用
收藏
页码:206 / 215
页数:10
相关论文
共 50 条
  • [21] The role of presepsin in pediatric patients with oncological and hematological diseases experiencing febrile neutropenia
    Cerasi, Sara
    Leardini, Davide
    Lisanti, Nunzia
    Belotti, Tamara
    Pierantoni, Luca
    Zama, Daniele
    Lanari, Marcello
    Prete, Arcangelo
    Masetti, Riccardo
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [22] Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis
    Weber, Sarah
    Magh, Aaron
    Hogardt, Michael
    Kempf, Volkhard A. J.
    Vehreschild, Maria J. G. T.
    Serve, Hubert
    Scheich, Sebastian
    Steffen, Bjorn
    ANNALS OF HEMATOLOGY, 2021, 100 (06) : 1593 - 1602
  • [23] Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis
    Sarah Weber
    Aaron Magh
    Michael Hogardt
    Volkhard A. J. Kempf
    Maria J. G. T. Vehreschild
    Hubert Serve
    Sebastian Scheich
    Björn Steffen
    Annals of Hematology, 2021, 100 : 1593 - 1602
  • [24] Comprehensive survival profiling of bloodstream infections caused by different bacteria in hematological and oncological patients
    Weber, S.
    Scheich, S.
    Magh, A.
    Hogardt, M.
    Kempf, V. A. J.
    Vehreschild, M. J. G. T.
    Serve, H.
    Steffen, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 200 - 200
  • [25] Airway Management by Tracheostomy in ChildrenWith Hematological and Oncological Diseases
    Nakatani, Naoko
    Saito, Atsuro
    Katayama, Daisuke
    Ichikawa, Takayuki
    Noguchi, Jun
    Nakamura, Sayaka
    Tamura, Akihiro
    Kozaki, Aiko
    Kishimoto, Kenji
    Mori, Takeshi
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S40 - S41
  • [26] PREVALENCE OF HEPATITIS-C VIRUS FOLLOWING POLYTRANSFUSION IN PATIENTS WITH HEMATOLOGICAL AND ONCOLOGICAL DISEASES
    GUTENSOHN, K
    KNODLER, B
    ZELLER, W
    KRUGER, W
    ECKARDT, N
    HOSSFELD, DK
    KUHNL, P
    INFUSIONSTHERAPIE UND TRANSFUSIONSMEDIZIN, 1992, 19 (01): : 19 - 22
  • [27] EVALUATION OF CEFOPERAZONE IN THE TREATMENT OF BACTERIAL-INFECTIONS IN PATIENTS WITH HEMATOLOGICAL DISEASES
    ICHIMARU, M
    TAKATSUKI, K
    NIHO, Y
    SAWAE, Y
    CLINICAL THERAPEUTICS, 1984, 7 (01) : 60 - 68
  • [29] Seroprevalence of SARS-CoV-2 antibodies in patients with hematological and oncological diseases in early 2024
    Louise M. Cremer
    Jannik Stemler
    Rosanne Sprute
    Sebastian Herrmann
    Theresa Markus
    Jon Salmanton-García
    Lutz Gieselmann
    Veronica Di Cristanziano
    Henning Gruell
    Oliver A. Cornely
    Sibylle C. Mellinghoff
    Blood Research, 2025, 60 (1)
  • [30] Prophylaxis of bacterial Infections and Pneumocystis jirovecii pneumonia in Female Patients with hematological and oncological Diseases: Updated Guideline of the Working Group on Infections (AGIHO) of the German Society for Hematology and Oncology (DGHO)
    Classen, A. Y.
    Henze, L.
    von Lilienfeld-Toal, M.
    Maschmeyer, G.
    Sandherr, M.
    Duran, Graeff L.
    Alakel, N.
    Christopeit, M.
    Krause, S. W.
    Mayer, K.
    Neumann, S.
    Cornely, O. A.
    Penack, O.
    Weissinger, F.
    Wolf, H. -H
    Vehreschild, J. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 158 - 158